ABOS | Acumen Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-1.10 Insider Own15.53% Shs Outstand41.02M Perf Week-5.19%
Market Cap203.95M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float34.55M Perf Month25.13%
Income-45.00M PEG- EPS next Q-0.35 Inst Own77.20% Short Float / Ratio0.46% / 0.91 Perf Quarter-5.92%
Sales- P/S- EPS this Y79.00% Inst Trans6.22% Short Interest0.16M Perf Half Y-21.99%
Book/sh4.37 P/B1.13 EPS next Y-21.20% ROA-22.50% Target Price14.57 Perf Year38.48%
Cash/sh3.39 P/C1.45 EPS next 5Y9.70% ROE-23.40% 52W Range3.16 - 10.97 Perf YTD-8.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.06% Beta-
Dividend %- Quick Ratio16.40 Sales past 5Y- Gross Margin- 52W Low55.77% ATR0.53
Employees39 Current Ratio16.40 Sales Q/Q- Oper. Margin- RSI (14)49.39 Volatility7.68% 13.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.20% Profit Margin- Rel Volume0.37 Prev Close4.94
ShortableYes LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume175.41K Price4.93
Recom1.60 SMA20-5.82% SMA5011.24% SMA200-13.09% Volume64,974 Change-0.20%
Date Action Analyst Rating Change Price Target Change
May-18-23Initiated Cantor Fitzgerald Overweight $13
Jul-15-22Initiated BTIG Research Buy $15
Jun-30-22Initiated H.C. Wainwright Buy $15
Jan-21-22Upgrade BofA Securities Neutral → Buy $16 → $14
Jul-26-21Initiated UBS Buy $27
Jul-26-21Initiated Stifel Buy $27
Jul-26-21Initiated Credit Suisse Outperform $26
Jul-26-21Initiated BofA Securities Neutral $20
May-16-23 12:41PM
May-09-23 07:00AM
May-04-23 04:01PM
May-02-23 04:01PM
Apr-09-23 08:57AM
07:30AM Loading…
Mar-29-23 07:30AM
Mar-28-23 08:00AM
Mar-27-23 07:00AM
Mar-22-23 04:01PM
Mar-20-23 04:01PM
Mar-08-23 04:01PM
Feb-15-23 12:07PM
Feb-13-23 08:00AM
Jan-06-23 09:40AM
Jan-04-23 08:00AM
06:02AM Loading…
Dec-29-22 06:02AM
Nov-14-22 04:01PM
Nov-09-22 04:01PM
Nov-07-22 04:01PM
Nov-01-22 08:00AM
Oct-24-22 08:00AM
Sep-08-22 12:44PM
Aug-15-22 11:00PM
Aug-08-22 04:15PM
Aug-01-22 10:30AM
Jul-26-22 04:15PM
Jun-08-22 08:00AM
May-16-22 10:00PM
05:08PM Loading…
May-11-22 05:08PM
Apr-27-22 08:00AM
Apr-02-22 12:00AM
Apr-01-22 05:01PM
Mar-28-22 04:05PM
Mar-16-22 04:15PM
Dec-30-21 04:16AM
Nov-25-21 07:35AM
Nov-15-21 08:00AM
Nov-08-21 08:00AM
Nov-02-21 08:00AM
Oct-07-21 08:00AM
Oct-01-21 06:05AM
Aug-16-21 04:05PM
Jul-23-21 07:13PM
Jul-01-21 05:02PM
Jun-30-21 10:44PM
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zuga MattCFO and Chief Business OfficerDec 29Option Exercise1.1950,00059,50076,187Jan 03 05:23 PM